Intellia Therapeutics (NTLA) Announces Earnings Results

Intellia Therapeutics (NASDAQ:NTLA) issued its quarterly earnings results on Wednesday. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.05), MarketWatch Earnings reports. Intellia Therapeutics had a negative return on equity of 31.54% and a negative net margin of 284.56%. The business had revenue of $7.41 million for the quarter, compared to analysts’ expectations of $11.58 million. During the same quarter last year, the company earned ($0.44) earnings per share. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis.

Shares of NTLA opened at $16.98 on Thursday. The company has a market capitalization of $803.21 million, a P/E ratio of -9.03 and a beta of 3.13. Intellia Therapeutics has a 52-week low of $16.33 and a 52-week high of $35.99.

A hedge fund recently raised its stake in Intellia Therapeutics stock. Bank of New York Mellon Corp boosted its holdings in Intellia Therapeutics Inc (NASDAQ:NTLA) by 55.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 123,494 shares of the company’s stock after purchasing an additional 44,015 shares during the quarter. Bank of New York Mellon Corp owned about 0.29% of Intellia Therapeutics worth $3,379,000 as of its most recent SEC filing. 66.47% of the stock is currently owned by hedge funds and other institutional investors.



A number of equities analysts have recently commented on the company. Credit Suisse Group assumed coverage on Intellia Therapeutics in a research report on Monday. They set a “neutral” rating and a $24.00 price objective for the company. Cann reissued a “hold” rating on shares of Intellia Therapeutics in a research report on Thursday, October 18th. Oppenheimer reissued a “hold” rating on shares of Intellia Therapeutics in a research report on Wednesday. BidaskClub downgraded Intellia Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 26th. Finally, Zacks Investment Research raised Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research report on Saturday, August 4th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $38.70.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Read More: Insider Trading – What You Need to Know

Earnings History for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply